A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes

About this trial
This is an interventional treatment trial for Type 2 Diabetes focused on measuring Insulin glargine
Eligibility Criteria
Inclusion Criteria:
- Have T2DM based on the disease diagnostic criteria World Health Organization (WHO) classification.
- Have been receiving 2 or more OAMs at stable doses for the 12 weeks prior to screening.
- Have a HbA1c ≥7.0% and ≤11.0%.
- Body mass index (BMI) ≤35 kilograms per meter squared.
Exclusion Criteria:
- Have used insulin therapy (outside of pregnancy) anytime in the past 1 year, except for short-term treatment of acute conditions, and up to a maximum of 4 continuous weeks.
- Have used any glucagon like peptide (GLP-1) receptor agonists within the previous 90 days.
- Are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening.
- Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.
- Have had ≥2 emergency room visits or hospitalizations due to poor glucose control.
- Have known hypersensitivity or allergy to Lantus® or its excipients.
- Are receiving chronic systemic glucocorticoid therapy at pharmacological doses or have received such therapy within 4 weeks immediately preceding screening.
- Have obvious signs or symptoms, or laboratory evidence, of liver disease.
- Have one of the following concomitant diseases: significant cardiac or gastrointestinal disease.
- Have a history of renal transplantation, are currently receiving renal dialysis or have a serum creatinine greater than 2.0 milligrams per deciliter.
- Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia.
- Participants with active cancer or personal history of cancer within the previous 5 years.
- Are pregnant or intend to become pregnant during the course of the study.
- Are women who are breastfeeding.
Sites / Locations
- Anhui Provincial Hospital
- The First Affiliated Hospital of Lanzhou University
- Shantou University Medical College No.2 Affiliated Hospital
- Guangdong Province People's Hospital
- The First Affiliated Hospital, Sun-Yat Sen University
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
- The 1st Affiliated Hospital of Henan Science and technology
- Tongji Hosp Tongji Med Col Huazhong Univ of Sci & Tech
- Wuhan Central Hospital
- The First People Hospital of Yueyang
- Changzhou No.2 People's Hospital
- The Affliated Jiangyin Hospital of Southeast University Medical College
- Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med
- The Second Affiliated Hospital of Nanjing Medical University
- Nanjing First Hospital
- Nanjing Jiangning Hospital
- Wuxi People's Hospital
- Xuzhou central Hospital
- Affiliated Hospital of Jiangsu University
- No.2 Hospital Affiliated to Jilin University
- Siping central people's hospital
- Dalian Med. Univ. No 2 Affiliate Hospital
- Shengjing Hospital of China Medical University
- The First Affiliated Hospital with Nanjing Medical Universit
- General Hospital of Ningxia Medical University
- 1st affiliated Hospital of Shanxi Medical University
- Jinan Central Hospital
- West China Hospital of Sichuan University
- Peking Union Medical College Hospital
- Chongqing General Hospital
- Shanghai Putuo District Center Hospital
- Tianjin Medical University General Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
LY2963016
Lantus®
Insulin naive participants started on 10 units (U) LY2963016 given subcutaneously (SC) once a day (QD) for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the fasting blood glucose (FBG) ≤100 milligram per deciliter (mg/dL) (5.6 millimoles per litre [mmol/L]) while avoiding hypoglycemia. Participants were allowed to continue oral antihyperglycemic medication (OAM).
Insulin naive participants started on 10 U Lantus® given SC QD for 24 weeks. Participants-driven titration was supervised by investigators through the course of the study to maintain the FBG ≤100 mg/dL (5.6 mmol/L) while avoiding hypoglycemia. Participants were allowed to continue oral OAM.